C4 Therapeutics/$CCCC
1D1W1MYTD1Y5YMAX
Capital at risk
About C4 Therapeutics
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
- Ticker
- $CCCC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 104
- Headquarters
- Watertown, United States
- Website
- www.c4therapeutics.com
C4 Therapeutics Metrics
BasicAdvanced
$379M
-
-$0.91
2.95
-
Price and volume
Market cap
$379M
Beta
2.95
52-week high
$5.17
52-week low
$1.69
Average daily volume
2.2M
Financial strength
Current ratio
5.449
Quick ratio
5.285
Long term debt to equity
0.203
Total debt to equity
0.23
Profitability
EBITDA (TTM)
-99.448
Gross margin (TTM)
86.34%
Net profit margin (TTM)
-289.44%
Operating margin (TTM)
-288.34%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-19.25%
Return on equity (TTM)
-48.14%
Valuation
Price to revenue (TTM)
9.813
Price to book
1.53
Price to tangible book (TTM)
1.53
Price to free cash flow (TTM)
-4.026
Free cash flow yield (TTM)
-24.84%
Free cash flow per share (TTM)
-0.765
Growth
Revenue change (TTM)
2.33%
Earnings per share change (TTM)
-42.58%
3-year revenue growth (CAGR)
29.78%
3-year earnings per share growth (CAGR)
-31.72%
What the Analysts think about C4 Therapeutics
Analyst ratings (Buy, Hold, Sell) for C4 Therapeutics stock.
Analyst projections of the future price of C4 Therapeutics stock.
Bulls say / Bears say
Cemsidomide produced a 53% overall response rate at the 100 microgram dose and 40% at 75 micrograms in a heavily pre-treated multiple-myeloma Phase 1 cohort. No treatment-related discontinuations were reported and only 7% of patients needed dose reductions, supporting its potential as a tolerable, active treatment. (GlobeNewswire)
The Roche collaboration gives C4T external validation for its targeted-protein-degradation platform, as Roche will lead antibody design, development and commercialisation for two degrader-antibody conjugate programmes. C4T received $20 million upfront and is eligible for more than $1 billion in milestone payments plus royalties. (C4 Therapeutics)
Cemsidomide is moving beyond late-line monotherapy into combination treatment with Pfizer’s approved elranatamab, with the Phase 1b trial now dosing patients. This could widen its use in multiple myeloma if the combination improves immune response and remains tolerable. (C4 Therapeutics)
The strongest efficacy evidence is still from an early, non-randomised Phase 1 study, while the key Phase 2 MOMENTUM response-rate readout is not expected until the second half of 2027. That leaves a long period in which later-stage data could fail to reproduce the initial results. (C4 Therapeutics)
The Phase 1 data also showed Grade 3/4 neutropenia in 58% of patients. Even though C4T described it as manageable, this safety burden could restrict dosing, combinations or adoption in a competitive multiple-myeloma market. (GlobeNewswire)
C4T remains loss-making and raised $33.5 million through an at-the-market share sale during the second quarter, increasing dilution risk. Its stated cash runway to the end of 2028 also depends on management’s spending assumptions as it prepares additional trials and Phase 3 activities. (BioSpace, last10k.com)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
C4 Therapeutics Financial Performance
Revenues and expenses
C4 Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing C4 Therapeutics
AllUSDGBPEUR
Fund name | Fund size | $CCCC weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.